Introduction
Primary prevention of hemolytic disease of the fetus and newborn (HDFN) by administration of anti-D immunoglobulin to RhD-negative mothers has been a notable success story in modern obstetrics. However, despite receiving an anti-D prophylaxis after delivery, and in high-risk events during pregnancy, up to 2% of RhDnegative mothers become immunized and the HDFN
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Fetal RHD testing at 24-26 weeks is highly accurate and can be used to target routine antenatal anti-D prophylaxis as well as postnatal prophylaxis. Costeffectiveness was achieved by centralizing and avoiding any additional costs to the antenatal care system. remains a problem for affected women and their fetuses (1) . For example, in Finland, the prevalence of anti-D antibodies in pregnant RhD-negative women has until now been 1.8%, and over 80% of severe immunizations requiring intrauterine transfusions are caused by anti-Dantibodies (2) . To prevent these residual cases of immunization, routine antenatal anti-D prophylaxis (RAADP) has been offered to all RhD-negative women at the beginning of the third trimester in North America, Australia, the UK and many other European countries since the mid-1990s.
As a result of the discovery of cell-free fetal DNA in maternal plasma in the 1990s, detection of the fetal RHD gene now offers a tool for non-invasive determination of the fetal RHD type (3, 4) . With real-time PCR used as a large-scale screening method, sensitivities close to 100% have been reported (5-7). Thus, it is possible to target RAADP solely at the RhD-negative women who are carrying an RhD-positive fetus and to avoid unnecessary treatment in approximately 40% of women who are not at risk of immunization. The main challenge for a targeted RAADP program is the low amount of fetal cell-free DNA present in maternal plasma, resulting in false negatives, withholding of necessary prophylaxis and a consequent risk of immunization (8) . The costs of targeted RAADP compared with the costs of RAADP given to all RhD-negative women need to be considered carefully.
In Scandinavia, a national targeted RAADP program including fetal RHD screening was implemented first in Denmark in 2010 (6), followed by Finland, where in October 2013, the National Institute for Health and Welfare announced new recommendations for maternity clinics to give anti-D prophylaxis to all non-sensitized RhD-negative pregnant women between 28 and 30 weeks of gestation (9) . To avoid unnecessary treatment in these women, screening of fetal RHD was introduced at the beginning of 2014, centralized to the national antenatal blood group antibody screening program carried out by the Finnish Red Cross (FRC) Blood Service. Here, we report the outcome of the first two years of fetal RHD screening and the compliance rate with the RAADP program in Finland.
Material and methods
To assess the accuracy of the fetal RHD screening test, we prospectively collected data on all RhD-negative women (12% of the population) participating in the national screening program for HDFN in Finland in 2014 and 2015. At the first visit to the maternity clinic at 8-12 weeks of gestation, all women were tested for the ABO and RhD blood groups and screened for red cell antibodies. RhD-negative women were screened again at 24-26 and 36 weeks. The fetal RHD screening was offered to all non-immunized RhD-negative women at 24-26 weeks, at the same time as the second antibody screening. When indicated by the result, anti-D prophylaxis was given at the next routine visit to the maternity clinic at 28-30 weeks (Figure 1) .
The main outcome variable was the accuracy of the fetal RHD assay: sensitivity, specificity, false-negative rate, and false-positive rate, with postnatal serology used as the reference standard. The secondary variable was the compliance rate with the newly introduced RAADP program.
Antenatal screening tests were performed in the FRC Blood Service laboratory in accordance with the national screening program. Maternal blood samples were drawn at local laboratories or maternity clinics and transported by mail or courier services to the laboratory within a few days. Newborn RhD typing was performed serologically from cord or heel stick samples at local laboratories, where the result was systemically compared with the fetal one. Discordant results were reported and the newborn samples sent to the FRC Blood Service laboratory for genotyping.
A description of the real-time PCR method (targeting the RHD exons 5 and 7) is available as Supporting Information Appendix S1 in the online version of this paper. The results were transferred electronically from the analysis software to the laboratory information management system. Automatically generated reports based on the fetal RHD result (positive/negative/inconclusive), including recommendations for administering anti-D immunoglobulin (250-300 lg) at 28-30 weeks of gestation, were sent to the maternity clinics mainly electronically. In cases of a negative fetal RHD result, antenatal prophylaxis was considered unnecessary. In all cases in which the fetus was RHD-positive or results were inconclusive, prophylaxis was recommended. Postnatal prophylaxis within 72 h of birth was based on a serologically determined newborn RhD test result.
A power analysis was performed before the start of the study to determine the necessary study size. A targeted prophylaxis program may not cause a higher number of immunizations than a non-targeted program, thus a falsenegative rate of less than 0.25% for the fetal RHD screening has been defined as critical (8) . Using a power analysis for binomial test it was estimated that 7200 samples would be needed to show a 0.15-0.25% difference in comparison with previously reported false-negative rates at a significance level of 0.05 and a power of 0.80. The diagnostic performance of the fetal RHD test was evaluated by comparing the PCR results with the serological RhD type of the newborn. Each statistical measure and their binomial 95% confidence intervals (CIs) were calculated using computer software R, version 3.3.1, and its add-on package epiR (10,11). 
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Results
During the study period (February 2014-January 2016), fetal RHD was screened from 10 814 women representing approximately 83.2% of the expected number of nonimmunized RhD-negative women. Table 1 summarizes the diagnostic performance of the assay.
The fetal RHD test result was positive in 7087 (65.5%) and negative in 3641 (33.7%) samples, with the result found inconclusive in 86 (0.8%) cases. One false-negative and seven false-positive results were reported by the delivery hospitals over two years. For the detection of fetal RHD, sensitivity was 99.99% (95% CI 99.92-99.99) and specificity 99.81% (95% CI 99.60-99.92). The falsenegative result was caused either by a sample mix-up in a hospital or too low a quantity of DNA in the sample. Two of the false-positive results most probably originated from contamination, three were caused by technical errors and two by fetal RHD variants. The negative predictive value of the test was 99.97% (95% CI 99.85-99.99). The turnaround time from sample enrollment to reporting was 5 days.
The majority of the inconclusive results (60/86, 69%) were due to mothers' RHD null variants, detected by low cycle threshold values representing high concentrations of RHD sequences. The most frequent variants were RHD*Ψ (RHD*08N.01; 18/60) and *DAU (RHD*10; 4/60), but more than half of the variants were not recognized by the SSP (sequence specific primers) kit (Inno-Train, www. inno-train.de). Only 15% (13/86) of the inconclusive results were due to fetuses' RHD variants. Many of the fetal variants were not detected because maternal DNA overpowers them in the screening test and the serological test after birth does not reveal null variants. The remaining 13 inconclusive results were due to a hemolytic sample and weak or variable amplification. Blood samples were taken after birth: 53 of them were positive and 32 negative; only one sample of a newborn was missing. The have not yet been sequenced. Using fetal RHD screening to target RAADP, unnecessary prophylaxis was avoided in 3641/10 814 (33.7%) cases (equivalent to 99.6% of the RhD-negative women carrying an RHD-negative fetus). Taking into account the inconclusive results with the RHD-negative newborn and the false-positive results, antenatal prophylaxis was unnecessarily administered to 39/10 814 (0.4%) women. In the only false-negative case resulting in antenatal prophylaxis being withheld, the woman received post-delivery prophylaxis based on the newborn result.
To assess compliance with the fetal RHD screening program, the FRC Blood Service laboratory database was searched for the total number of RhD-negative women screened for antibodies at 24-26 weeks. The database also checked whether fetal RHD had been requested and performed (sample uptake). The overall compliance rate was 69.7% for the first year after implementation, as healthcare areas joined the screening program without a set schedule. During the second year, compliance rose to 97.3% and by the end of the study period (the last six months), samples were taken from 98.3% of the RhDnegative women.
Discussion
Since the introduction of RAADP over 20 years ago, several studies have confirmed that it constitutes a costefficient method for reducing the RhD immunization risk by an additional 50-66% (1,12-15). However, today the appropriate clinical use of anti-D immunoglobulin is not only about evidence-based medicine and economics but is also a question of ethics and the availability of a human blood product. As RAADP given to all RhD-negative women would double the use of anti-D immunoglobulin, fetal RHD screening was implemented successfully in the existing antenatal care program in Finland, with over 98% coverage among RhD-negative women towards the end of the study period 2014-2016. The diagnostic accuracy of the fully automated PCR test was very high; our overall fetal RHD detection sensitivity of 99.99% (95% CI 99.92-99.99) was comparable to previous large-scale studies, enabling the use of RAADP to be reduced by more than a third.
The false-negative rate in the study was 0.014% (95% CI 0.0025-0.0799), which is similar to the level seen in the Netherlands (0.03%) (16) where the tests are likewise carried out after 24 weeks of gestation. Such a low false-negative rate not only fulfills the requirement for a successful targeted RAADP but will also allow discontinuation of newborn testing without risking the postnatal prophylaxis program, which is by far the most important intervention against HDFN. Moreover, de Haas et al. (16) pointed out that 0.09% of cord blood results are false-negative due to the presence of a variant RHD gene, resulting in the mistyping of the newborn as RhD-negative, or a mix-up with maternal samples, and therefore the serological method is actually less accurate than the real-time PCR. Our study confirms that fetal RHD testing at 24 weeks can be used as a single test to guide postnatal use of anti-D immunoglobulin (Figure 1) , a policy that has already been established in Denmark and in the Netherlands. Together with the high number of RhD-negative women participating in the national screening program, this means that the omission of cord blood or heel stick serology is also possible in Finland, a change that will further minimize the costs of the program. Serological RhD typing of the newborn can be restricted to the rare cases where no sample for the fetal RHD screening was obtained or the result was inconclusive. Another possibility is to discontinue serology only for the assigned fetal RHD-positive cases for whom prophylaxis is imperative.
The rate of false-positive results is inversely proportional to the rate of inconclusive results and depends on the algorithms applied to result interpretation. Irrespectively, both results will lead to unnecessary administration of anti-D prophylaxis. In our test design, the false-positive rate was only 0.19% (95% CI 0.093-0.396), which is well in line with the 0.32% rate seen in Denmark and the 0.57% rate in the Netherlands (16, 17) . Our rate of inconclusive results, 0.8% (95% CI 0.644-1.445), is higher than the 0.21% rate achieved in the Netherlands but far lower than the rate of 2.2% reported for Denmark. However, the numbers are not fully comparable due to different algorithms used in result interpretation and particularly due to the different study populations. Originally, we chose to interpret fetal results by strict criteria, including unambiguous results from the two exons. We allowed the result to be inconclusive in order to receive the newborn samples with discrepant results from the delivery hospitals, which enabled us to study the genetic background for these results in our population. Now, with the RHD-screening procedure thoroughly validated, our algorithm can be changed to further reduce the number of inconclusive results; the fetal RHD genotype can be determined on the basis of the amplification of RHD exon 5 in the case of a maternal RHD variant. For the Finnish screening program, the current 0.4% rate of unnecessarily administered anti-D prophylaxis is, however, already perfectly acceptable.
The number of RHD variants depends on the study population and varies from 0.3% in Sweden (7) to 1.3% in the UK with a highly admixed multiethnic population (5). In our study, 0.6% (95% CI 0.432-0.715) of samples contained a maternal variant allele; the same proportion of variants was detected in Denmark using a two-exon method similar to ours (6) . In Sweden, the small number of variants can be explained by their single-exon method that does not unveil RHD variants to the same degree. However, such a pragmatic test design is only possible if the genetic background of the pregnant population and the immunization risk associated with different variants is known. In our study, up to 35% of the variant carriers are assumed to carry a variant allele that gives rise to a negative RhD phenotype but where the screening test detects the maternal allele. Interestingly, all these women were apparently of Caucasian origin. Sequencing these as yet unknown RHD variant alleles will offer new information about RHD genetics in the Finns and can be used to further increase the accuracy of fetal RHD screening.
The high accuracy of our fetal RHD screening test rests on full automation of the entire process. Electronic sample tracking preventing sample mix-ups together with the automated DNA extraction and PCR set-up were effective in preventing handling errors and restricting aberrations in the laboratory. In addition to the analysis software algorithm being based on strict thresholds for result interpretation, two persons separately evaluated the results visually to avoid false-negative results. All the data were electronically transferred and reports generated automatically, which not only minimized human error but also saved resources. Our basic principle was to keep the assay simple to eliminate errors as well as extra costs. As the amount of fetal cell-free DNA is critical to the accuracy of the test, total cell-free DNA or similar controls are used in many other laboratories. As there are no controls for the presence of fetal cell-free DNA suitable for screening tests, we did not use any internal controls but instead optimized cell-free DNA extraction and increased the proportion of DNA in the PCR reaction to maximum. Accordingly, we did not request new samples in inconclusive cases to keep up with the original screening program and to ensure timely administration of RAADP.
Innovative studies from Sweden and the UK report that fetal RHD testing can be performed already from 11 weeks onwards with a sensitivity of up to 99.8% (7, 18) . In Sweden, a national first trimester screening policy was adopted in 2016 allowing targeted use of anti-D immunoglobulin for invasive procedures in early pregnancy and late miscarriages in addition to RAADP. In their cost-effectiveness analysis of the first trimester test, when adjusted for their current sensitivity of 99.8%, allowing 0.2% of false-negative cases, the cost was found higher in the targeted prophylaxis group than in the nontargeted group due to the higher number of immunizations resulting from the low number of false-negatives in the former group (19) . Thus, although the use of the first trimester screening is very tempting, the authors concluded that for a targeted RAADP program to be costeffective, the sensitivity of the fetal RHD test needs to be higher, close to 100%. However, when compared with no RAADP, the targeted prophylaxis resulted in a lower immunization risk and lower costs because treatment of severe immunization is extremely expensive.
Cost-effectiveness of a targeted RAADP program depends on the cost of the fetal RHD test and anti-D immunoglobulin, the indirect costs to the maternity care system, and also compliance with the policy of administering anti-D prophylaxis. According to the study by Neovius et al. (19) , targeted RAADP generates cost savings at a screening test price of €47. In Finland, the current price of €29 was achieved by centralizing the testing to the FRC Blood Service, allowing high-performance testing of a considerable number of samples (about 6000 per year), which reduced reagent, quality control and human resource costs. Most importantly, additional costs to the antenatal care system were avoided because samples for the fetal test are taken, transported and registered at the same time as the second antibody screening sample. The FRC Blood Service antenatal laboratory offered full support to the maternity clinics in communal health centers, which had no previous experience of anti-D prophylaxis, and compliance with the targeted RAADP program rose rapidly from 70% in 2014 to over 98% today. Moreover, the Finnish RhD-negative women were found to be highly motivated to have anti-D prophylaxis when carrying a positive fetus, which is essential for achieving a clinical effect.
The strength of this study lies in its large series of fetal RHD tests, comprising almost the entire RhD-negative pregnant population (including multiple pregnancies); only women with previous anti-D immunizations were excluded from the results. Most importantly, this is a reallife study evaluating test performance in a routine setting, including the logistic challenges and weather conditions in a country where geography is a major issue. To avoid any additional costs, the samples were drawn and transported from all over Finland to the FRC Blood Service laboratory located in Helsinki along with the antibody screening samples. For the same reason, the newborn RhD typing tests were performed by the 27 delivery hospitals, also responsible for comparison of the fetal and newborn results, which can be considered a limitation of this study. It is possible that, especially in the beginning, not all discordant results were reported by the delivery hospitals. However, as onethird of the comparisons were performed electronically without significantly different results, we could calculate the number of false-negative test results to be equally low.
In conclusion, the targeted RAAPD program was implemented effectively in the national maternity care program in Finland. The accuracy of the screening test for fetal RHD status was excellent. Our aim is to discontinue cord blood typing of newborns, which would further improve cost-efficiency. However, in order not to risk the postnatal prophylaxis program, this change in a routine that has been in place in the delivery hospitals for almost 50 years needs to be carefully orchestrated. In the future, the clinical effect of the RAADP program on RhD immunization rate needs to be studied during the subsequent pregnancies of these women.
